ClinicalTrials.gg

Program

SOS1 Inhibitor MRTX0902

Its studies are mostly in Gastrointestinal Stromal Tumors · Hematologic Neoplasms, led by Kumquat Biosciences.

Furthest: phase 2, since Jan 23, 20263 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kumquat Biosciences33 open or runningphase 2since Jan 23, 2026Jul 1, 2024Dec 31, 2026phase 1 · NCT06507306

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 1, 2024First study: phase 1 study in Solid Tumor, AdultFirst studyNCT06507306 · 92 enrolled · United States, France, Italy and more
  2. Oct 2, 2024Phase 1 study in Hematologic NeoplasmsNCT06645886 · 13 enrolled · United States, France, Germany and more
  3. Jan 23, 2026Phase 2 study in Gastrointestinal Stromal TumorsPhase 2 reachedNCT07406633 · 46 planned · United States

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Solid Tumor, AdultNCT06507306
  2. Mar 2027Primary completion: phase 1 study in Hematologic NeoplasmsNCT06645886
  3. Oct 2027Primary completion: phase 2 study in Gastrointestinal Stromal TumorsNCT07406633

TargetBeta

“An orally available inhibitor of the guanine nucleotide exchange factor (GEF) Son of sevenless homolog 1 (SOS1), ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07406633Gastrointestinal Stromal Tumors · United States2RecruitingOct 202746
NCT06645886Hematologic Neoplasms · United States, France, Germany and more1Active, not recruitingMar 202713
NCT06507306Solid Tumor, Adult · United States, France, Italy and more1Active, not recruitingDec 31, 202692

How it is read

Names in the registry

  • “KQB198”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.